CombiGene

CombiGene AB is a Swedish biotechnology company focused on developing innovative gene therapies for patients with severe neurological diseases, particularly those suffering from epilepsy who lack effective treatment options. The company aims to enhance the quality of life for these patients through its proprietary approach, which utilizes an adeno-associated viral vector to deliver a combination of neuropeptide Y and its receptor Y2 to the specific area of the brain where epileptic seizures originate. CombiGene has completed significant preclinical studies that have yielded positive results, and it is preparing to conduct mandatory safety studies. If these safety evaluations are successful, the company plans to initiate human clinical trials for its lead therapy candidate, CG01, further advancing its mission to provide new therapeutic options for patients in need.